Can a Two-Drug combo tame a rare blood cancer?

NCT ID NCT06159491

Recruiting now Disease control Sponsor: Douglas Tremblay Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing whether combining two drugs, pacritinib and azacitidine, can help people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The study includes adults who are newly diagnosed or have had limited prior treatment. The goal is to find the safest dose and see if the combination can shrink the disease or improve blood counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pacritinib combined with azacitidine
What this could lead to: If successful, this combination could offer a new treatment option for people with chronic myelomonocytic leukemia, potentially improving response rates and disease control.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits are uncertain. The combination may cause side effects, and the response rate may not be high enough to warrant further study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelomonocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOMONOCYTIC LEUKEMIA

Contacts and locations

Locations

The Mount Sinai Hospital
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.